Immune system cells via paracrine immunomodulation

Immune system cells via paracrine immunomodulation refers to a physiological process and therapeutic mechanism where the local immune environment is altered through the secretion of soluble factors rather than direct molecular targeting of a single receptor. This mechanism is most prominently associated with Mesenchymal Stem Cells (MSCs), which function as 'injury drugstores' by releasing anti-inflammatory cytokines, growth factors, and extracellular vesicles in response to inflammatory signals (Caplan & Correa, 2011). These secreted mediators, such as IL-10, TGF-beta, and PGE2, act on surrounding immune cells to suppress effector T-cell proliferation and promote the induction of regulatory T-cells (Kyurkchiev et al., 2014). This multi-targeted approach is particularly valuable for treating complex, multi-factorial inflammatory conditions like Graft-versus-Host Disease (GvHD) and autoimmune disorders where a single-target drug may be insufficient (Galipeau & Sensébé, 2018). Because this term describes a broad cellular interaction and secretome-mediated effect, it is classified as a mechanism of action or a biological process rather than a discrete molecular target. Consequently, while it is a central concept in regenerative medicine and cell therapy, it does not represent a single protein or gene entity (Pittenger et al., 2019).

Other names

Paracrine immunomodulationBystander effectSecretome-mediated immune regulationMSC-mediated immunomodulationCell-mediated paracrine signaling

Therapeutic agents, primarily mesenchymal stem cells (MSCs), act by sensing the local inflammatory environment and secreting a variety of bioactive molecules—including cytokines (IL-10, TGF-beta), chemokines, and enzymes (IDO)—that modulate the activity of nearby immune cells such as T-cells, B-cells, and macrophages without requiring direct cell-to-cell contact (Galipeau & Sensébé, 2018; Caplan & Correa, 2011).